Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy
Go back to Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 24.35 +0.37 (1.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $23.98 | 52 Week High | $117.12 | |||
| Open | $24.08 | 52 Week Low | $46.52 | |||
| Day High | $24.81 | P/E | N/A | |||
| Day Low | $24.01 | EPS | $-1.97 | |||
| Volume | 1,846,693 | |||||
